Advertisement
Document › Details
Sanofi S.A.. (3/6/18). "Press Release: Sanofi’s Board of Directors Proposes Appointment of Emmanuel Babeau as New Independent Director". Paris.
> Creates new Scientific Committee and nominates Thomas Südhof as Chair
> Appoints Fabienne Lecorvaisier as Chair of the Audit Committee
At its meeting held on March 6, 2018, Sanofi’s Board of Directors proposed to submit the appointment of Emmanuel Babeau as new independent director, as well as the renewal of the terms of Olivier Brandicourt, Patrick Kron and Christian Mulliez to a shareholders’ vote during the general shareholders’ meeting on May 2, 2018. Robert Castaigne, board member since 2000 and current Chair of the Audit Committee, will not seek a new term. Fabienne Lecorvaisier will succeed him as Chair of the Audit Committee. The Board has also created a new Scientific Committee, which will be led by Thomas Südhof.
Emmanuel Babeau is Deputy Chief Executive Officer and Chief Financial Officer of Schneider Electric Group, a position he has held since April 2013. He joined Schneider Electric in 2009 as Chief Financial Officer. Before joining Schneider Electric Group, he was Group Chief Financial Officer of Pernod Ricard SA from 2003 to 2009. Emmanuel Babeau graduated from Ecole supérieure de commerce de Paris in 1989 with a degree in accounting and financial.
“Throughout his career Emmanuel Babeau led successful acquisitions and developed strong financial skills with an international mindset that will be strong additions to our Board. We are confident that his contribution to Sanofi’s strategy will be beneficial in bringing innovative medicines to the market,” said Serge Weinberg, Chairman of the Board, Sanofi. “I would like to thank Robert Castaigne for his strong contribution to the board and as Chairman of the Audit Committee since March 2015 and wish all the best to Fabienne Lecorvaisier who will succeed him as Chair of the Audit Committee.”
About Sanofi
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
Sanofi, Empowering Life
CONTACTS
Media Relations Contact
Nicolas Kressmann
Tél.: +33 (0)1 53 77 46 46
mr@sanofi.com
Investor Relations Contact
George Grofik
Tél.: +33 (0)1 53 77 45 45
ir@sanofi.com
Record changed: 2023-06-05 |
Advertisement
More documents for Sanofi (Group) [since May 2011]
- [1] GenSight Biologics S.A.. (12/22/23). "Press Release: GenSight Biologics Appoints Laurence Rodriguez as Chief Executive Officer". Paris....
- [2] Sanofi S.A.. (12/11/23). "Press Release: Statement on FTC Challenge to Proposed License Agreement with Maze Therapeutics". Paris....
- [3] Aqemia S.A.S.. (12/5/23). "Press Release: Aqemia Announces a Major Multi-year Collaboration of $140 Million with Sanofi". Paris....
- [4] Eligo Bioscience S.A.. (12/5/23). "Press Release: Eligo Bioscience Raises $30 Million To Write a Novel Chapter for Genetic Medicines". Paris....
- [5] MeiraGTx Holdings plc. (10/30/23). "Press Release: MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities". London & New York, NY....
- [6] Sanofi S.A.. (10/3/23). "Press Release: Sanofi Announces Agreement for Potential First-in-Class Vaccine against Extraintestinal Pathogenic E. coli". Paris....
- [7] Sanofi S.A.. (3/13/23). "Press Release: Sanofi to Acquire Provention Bio, Adding to Portfolio TZIELD, the First Disease-modifying Treatment for the Delay of Stage 3 Type 1 Diabetes (T1D)". Paris & Red Bank, NJ....
- [8] Avilar Therapeutics, Inc.. (2/16/23). "Press Release: Avilar Therapeutics Increases Financing to $75 Million to Advance Pipeline of Novel Extracellular Protein Degraders". Waltham, MA....
- [9] Sanofi S.A.. (1/11/23). "Press Release: Sanofi Ventures Announces Multi-year Capital Commitment from Sanofi, Increasing Evergreen Fund to $750M". Paris....
- [10] CureVac N.V.. (1/10/23). "Press Release: CureVac Appoints Alexander Zehnder as CEO from April 1, 2023". Mainz & London....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top